Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All

Sudhakar, Padhmanand; Alsoud, Dahham; Wellens, Judith; Verstockt, Sare; Arnauts, Kaline; Verstockt, Bram; Vermeire, Séverine

doi:10.1093/ecco-jcc/jjac027

Cited by 16 publications

(18 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multi-omics studies consisting of meta transcriptomics, metaproteomic, and metabolomics offer a great chance to fill knowledge gaps in IBD pathogenesis for a better understanding of CRC development as well as its classification into different molecular subtypes for patient stratification and the development of new biomarkers and targeted therapies [ 15 ] ( Figure 2 ).…”

Section: Omics: Future Directionsmentioning

confidence: 99%

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Nardone¹,

Zammarchi

Santacroce

et al. 2023

Cancers

View full text Add to dashboard Cite

Patients affected by inflammatory bowel disease (IBD) have a two-fold higher risk of developing colorectal cancer (CRC) than the general population. IBD-related CRC follows a different genetic and molecular pathogenic pathway than sporadic CRC and can be considered a complication of chronic intestinal inflammation. Since inflammation is recognised as an independent risk factor for neoplastic progression, clinicians strive to modulate and control disease, often using potent therapy agents to achieve mucosal healing and decrease the risk of colorectal cancer in IBD patients. Improved therapeutic control of inflammation, combined with endoscopic advances and early detection of pre-cancerous lesions through surveillance programs, explains the lower incidence rate of IBD-related CRC. In addition, current research is increasingly focused on translating emerging and advanced knowledge in microbiome and metagenomics into personalised, early, and non-invasive CRC screening tools that guide organ-sparing therapy in IBD patients. This review aims to summarise the existing literature on IBD-associated CRC, focusing on new insights into the alteration of the intestinal barrier and the interactions with the gut microbiome as the initial promoter. In addition, the role of OMIC techniques for precision medicine and the impact of the available IBD therapeutic armamentarium on the evolution to CRC will be discussed.

show abstract

Section: Omics: Future Directionsmentioning

confidence: 99%

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Nardone¹,

Zammarchi

Santacroce

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…The totality of environmental exposures to which an individual is subjected over the course of a lifetime is described by the “exposome” and might be able to complement the genome and explain the heritability gap that is encountered in IBD. 62 , 63 …”

Section: How To Predict Response To Diet In Ibd?mentioning

confidence: 99%

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives

Wellens

Vissers

Matthys³

et al. 2023

PGPM

View full text Add to dashboard Cite

Inflammatory bowel diseases (IBD) are chronic and incurable conditions of the gastro-intestinal tract with an increasing incidence and prevalence worldwide. Common symptoms are abdominal pain, diarrhea, and weight loss. Despite recent advances in medical management, many patients fail to achieve clinical remission and healing of the mucosa of the bowel. The cause is thought to involve an inappropriate reaction of the immune system, the microbiome and the environment in genetically susceptible individuals, leading to chronic bowel inflammation. Evidence is emerging that diet is a key environmental factor that might influence disease onset and course, and therefore may become a therapeutic strategy to mitigate inflammation and symptoms. Since IBD is a heterogeneous disease on a clinical and a molecular level, personalizing dietary advice could be the crucial factor to achieve long-lasting changes in dietary behaviors that could not only improve nutritional status but also tackle gut inflammation and abdominal symptoms on an individual level. In this review, we first discuss different aspects of personalized nutrition, namely the level, focus, and scope of personalized dietary regimens. Then, we provide a framework for the different goals of nutritional therapy in IBD and current evidence for personalized dietary approaches. Lastly, we discuss the need for adequate trial designs, access to the right data types and the bioinformatic tools that are necessary to develop algorithms that will allow us to move from general “healthy eating” advice to truly personalized nutritional plans for the individual IBD patient.

show abstract

“…However, examining time-dependent changes in omic profiles require large cohorts with systematic periodic gathering of samples. The collaborative efforts to generate and analyse multiomic data to shed insight into disease pathogenesis such as the Human Microbiome Project (HMP and HMP2/IBDMBD), The Dutch 1000 IBD initiative and the Pediatric RISK and PROTECT cohorts are critically important steps to advance the field [22,23].…”

Section: Gaps In Literature and Future Directionsmentioning

confidence: 99%

Precision medicine: how multiomics will shape the future of inflammatory bowel disease?

Ananthakrishnan

2022

Current Opinion in Gastroenterology

View full text Add to dashboard Cite

Purpose of reviewIn this article, we provide an overview of studies examining multiomic profiling in various clinical scenarios in the management of inflammatory bowel diseases (IBDs).Recent findingsIBD arises as a result of an interplay between genetic, environmental, microbial and immunologic perturbations. The access to high throughput technology as well as the decrease in costs associated with such studies has led to a growing wealth of literature examining the utility of single or multiomic profiles in the management of IBD. Such studies have commonly examined the genome (and less frequently the epigenome), transcriptome, metabolome, proteome and the gut microbial metagenome in the context of overall IBD status or specific clinical scenarios, including the disease progression or response to treatment. The findings have provided important insight into how each of these compartments reflect underlying disease pathophysiologic processes and, in turn, can influence stratification of patients for clinical management.SummaryMultiomic profiling in IBD has the potential to advance the field of personalized precision medicine in the management of IBDs.

show abstract

Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All

Cited by 16 publications

References 130 publications

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Inflammation-Driven Colorectal Cancer Associated with Colitis: From Pathogenesis to Changing Therapy

Personalized Dietary Regimens for Inflammatory Bowel Disease: Current Knowledge and Future Perspectives

Precision medicine: how multiomics will shape the future of inflammatory bowel disease?

Contact Info

Product

Resources

About